Abstract The present study was designed to explore the effects of low-toxicity Embelin on TRAIL-induced apoptosis and its possible mechanism in human leukemia cells. Our study showed that low-toxicity Embelin enhanced TRAIL-induced apoptosis through DR4 and DR5 upregulation and caspase activation in HL-60 cells. Pancaspase inhibitor Z-VAD-FMK inhibited cell apoptosis induced by TRAIL alone or combined with low-toxicity Embelin, which indicated the cytotoxic effect is mediated by caspase-dependent apoptosis. Although Embelin is an X chromosome-linked inhibitor-of-apoptosis protein (XIAP) inhibitor, an XIAP independent effect on cell death was detected in HL-60 cells exposed to lowtoxicity Embelin and TRAIL. Low-toxicity Embelin upregulated DR4 and DR5 expression to enhance TRAILinduced apoptosis. The sensitizing effects of Embelin on TRAIL-induced apoptosis were markedly attenuated when DR4/DR5 was knocked down. These data suggested that low-toxicity Embelin enhanced TRAIL-induced cell apoptosis through DR4 and DR5 upregulation, indicating that combination of low-toxicity Embelin and TRAIL may become as a potential antileukemia strategy.
Introduction
As a member of the TNF superfamily, TNF-related apoptosis inducing ligand (TRAIL) has been shown to induce apoptosis in many tumor cells but not in normal cells [1] . There are five TRAIL receptors including death receptor4 (DR4,TRAIL-R1), death receptor5 (DR5,TRAIL-R2), decoy receptor1 (DcR1, TRAIL-R3), DcR2 (decoy receptor 2, TRAIL-R4), and osteoprotegerin (OPG) [2] . Both DR4 and DR5 have a cytoplasmic death domain (DD) which mediates TRAILinduced apoptosis. DcR1 lacks DD, and DcR2 only has truncated DD which could not transduce apoptotic signaling to inhibit apoptosis [3, 4] . OPG is a TRAIL receptor and not homologous to the other four receptors. It inhibits osteoclasia and could not transduce apoptotic signaling after binding with TRAIL [5] . TRAIL can activate DR4 and DR5 and initiate a series of reactions which result in caspase-8 activation. Activated caspase-8 then initiates the caspase cascade and eventually activates effector caspases including caspase-3.
Although TRAIL can induce tumor cell apoptosis, there are some cancer cells resistant or less sensitive to TRAIL. The mechanism may involve abnormal expression of DR4/5, DcR1/2, cellular FLICE-like inhibitory protein (cFLIP), and X chromosome-linked inhibitor-of-apoptosis protein (XIAP) [6] [7] [8] [9] . It has become an effective combination of TRAIL and chemotherapeutics. More recently, Embelin was identified as a cell-permeable, small molecular weight inhibitor of the X chromosome-linked inhibitor-of-apoptosis protein (XIAP), an antiapoptotic protein, through second mitochondrial activator of caspase (smac) structure-based computational screening of a traditional herbal medicine three-dimensional structure database of 8221 individual traditional herbal products [10] . Embelin has been shown to bind with BIR3 of XIAP and release caspase-9 which will initiate caspase cascades and lead to apoptosis. Our previous study found that Embelin induced apoptosis by XIAP downregulation and caspase activation in acute myeloid leukemia cell line HL-60 [11] . In this study, we further evaluated the possibility of Embelin enhancing TRAIL-induced apoptosis in leukemia cells and explored the possible mechanism involved.
Results
TRAIL-induced cell apoptosis of HL-60 cells, and low-toxicity Embelin-enhanced TRAIL-induced apoptosis HL-60 cells were treated with Embelin of 3-300 μg/ml for 6-48 h, and MMT assay showed that 10 μg/ml Embelin was a low-toxicity concentration for HL-60 cells because the cell proliferation inhibition rate was less than 10 % at 24 h (Fig. 1a) . HL-60 cells were treated with TRAIL of 1-100 ng/ml for 6-48 h, and MMT assay showed TRAIL-inhibited cell proliferation (Fig. 1b) . The cell proliferation inhibition rate was 22.50 ±2.42 % at 10 ng/ml for 24 h. Therefore, TRAIL of 10 ng/ml and Embelin of 10 μg/ml were used for further investigations. MTT assay showed that low-toxicity Embelin could increase TRAIL-mediated cell proliferation inhibition (Fig. 1c) . Annexin V-FITC/PI double staining and flow cytometry analysis showed that TRAIL could induce apoptosis in HL-60 cells, which could be enhanced by lowtoxicity Embelin (Fig. 1d, e) . And the inhibition on cell proliferation was almost completely abrogated by pancaspase inhibitor Z-VAD-FMK (Fig. 1c) , which suggested that TRAIL alone or combined with low-toxicity Embelin inhibits cell proliferation through inducing apoptosis. Hoechst 33258 staining and fluorescent microscopy observation confirmed cell apoptosis induced by TRAIL alone or combined with low-toxicity Embelin (Fig. 1f) .
Apoptosis induced by TRAIL alone or combined with low-toxicity Embelin involves both the extrinsic and intrinsic pathways To explore the possible pathways involved in apoptosis induced by TRAIL combined with low-toxicity Embelin, we analyzed the expression of caspase-3, 8, and 9 ( Fig. 2a-c) . Caspase-3 is an effector caspase involved in both extrinsic and intrinsic pathways. Our results showed Embelin and TRAIL alone or combined with low-toxicity Embelin could activate caspase-3. Although increased caspase-9 and caspase-3 activation can result from XIAP inhibition of Embelin, increased caspase-8 activation may indicate intrinsic changes in the membrane proximal death signaling module. Active caspase-8 could induce activation of both type 1 (direct caspase-3 activation) and type 2 (mitochondrial) pathways.
Our results showed that in all of these caspases, cleavage was elevated when HL-60 cells were treated with TRAIL combined with low-toxicity Embelin, which suggested that both extrinsic and intrinsic pathways were activated. However, XIAP expression showed no obvious changes which is consistent with our previous study [11] (Fig. 2d) . This result suggested that the mechanism of Embelin enhancing TRAIL-induced apoptosis was not closely associated with XIAP expression. We also detected other factors which could contribute resistance or less sensitivity to TRAIL in HL-60 cells. Western blot results showed that low-toxicity Embelin did not influence the cFLIP (including cFLIP L and cFLIP S ), DcR1, and DcR2 expression.
Embelin-enhanced TRAIL-induced apoptosis parallels DR4 and DR5 upregulation
In consideration of the important role of DR4 and DR5 expression played in sensitivity to TRAIL in many tumor cells, we analyzed the DR4 and DR5 expressions at both transcriptional and post-transcriptional levels, respectively. The results showed that low-toxicity Embelin could increase the expressions of DR4 and DR5 messenger RNA (mRNA) (Fig. 3a) and proteins ( Fig. 3b ), which suggested that the possible mechanism of low-toxicity Embelin enhancing the TRAIL-induced apoptosis of HL-60 cells may involve DR4 and DR5 upregulation. We further analyzed surface expression of DR4 and DR5 by flow cytometry because surface expressions are actually functional. As low-toxicity Embelin increased DR4 and DR5 expressions at 24 h ( Fig. 3c-e) , we pretreated HL-60 cells with Embelin of 10 μg/ml for 24 h, and then TRAIL of 10 ng/ml was added for another 24 h (Fig. 3f) . The MTT assay results showed that cell proliferation inhibition of Embelin pretreatment group was more efficient than Embelin and TRAIL simultaneously administrated group. Fig. 1 Effect of TRAIL alone or combined with Embelin at low-toxicity concentration on cell proliferation rates and cell apoptosis of HL-60 cells. a HL-60 cells were treated with Embelin of 3, 10, 30, 100, and 300 μg/ml for 6, 12, 24, and 48 h, and cell viability was determined by MTT assay. b HL-60 cells were treated with TRAIL of 1, 5, 10, 50, and 100 ng/ml for 6, 12, 24, and 48 h, and cell viability was determined by MTT assay. c HL-60 cells were treated with TRAIL of 10 ng/ml, Embelin of 10 μg/ml, and Z-VAD-FMK μmol/l for 24 h and cell viability was determined by MTT assay (the group assignment is showed in the figure). d HL-60 cells were treated with TRAIL of 10 ng/ml alone or combined with Embelin of 10 μg/ml for 6, 12,24, and 48 h, and cell apoptosis was determined by Annexin V-FITC/PI double staining and flow cytometry. *P<0.05 indicates significant difference versus control group (Student's t test). e Representative results at 24 h. f HL-60 cells were treated with TRAIL of 10 ng/ml alone or combined with Embelin of 10 μg/ml for 24 h then the cells were stained with Hoechst 33258 and observed by fluorescent microscopy (×40)
Knockdown of DR4 or DR5 by small interfering RNA (siRNA) attenuated the effect of Embelin on TRAIL-induced apoptosis of HL-60 cells To confirm the hypothesis that DR4 and DR5 were involved in the mechanism of low-toxicity Embelin signaling, we knocked down the DR4 and DR5, respectively. The relative mRNA expression showed reduction in DR4 and DR5 expressions, and corresponding transfection efficiency was 69.13±3.58 % and 71.24±3.40 %, respectively (Fig. 4a) . The Western blot results confirmed the transfection efficiency (Fig. 4b) . MTT assay showed that DR4 and DR5 knockdown did not influence the cell proliferation rates of HL-60 cells and had no cytotoxicity to HL-60 cells (Fig. 4c) . Annexin V-FITC/PI double staining and flow cytometry analysis showed that cell apoptosis was inhibited obviously after DR4 or DR5 knockdown (Fig. 4d) , which suggests that both DR4 and DR5 play a major role in TRAIL-induced apoptosis in HL-60 cells. DR4 and DR5 induction by low-toxicity Embelin is needed for TRAIL-induced apoptosis in HL-60 cells. Fig. 2 TRAIL of 10 ng/ml combined with low-toxicity Embelin increased the caspase-3, 8, and 9 but has no effect on XIAP expression. a-c HL-60 cells were treated with TRAIL of 10 ng/ml alone or combined with Embelin of 10 μg/ml for 6, 12, and 24 h, respectively, and cleaved caspase-3, 8, and 9 expressions were determined by Western blot. d HL-60 cells were treated with TRAIL of 10 ng/ml alone or combined with Embelin of 10 μg/ml for 24 h. XIAP and Bcl-2 expressions were determined by Western blot. The equal loading of protein was confirmed by probing with ß-actin. e HL-60 cells were treated with Embelin of 10 μg/ml for 24 h. The cFLIP L , cFLIP S , DcR1, and DcR2 expressions were determined by Western blot. The equal loading of protein was confirmed by probing with ß-actin Discussion Leukemogenesis is caused by uncontrolled proliferation, abnormal differentiation and apoptosis inhibition. The present chemotherapy could only relieve very few patients. New drugs including TRAIL are being developed for leukemia therapy. In this study, we showed that TRAIL inhibited cell proliferation rates in a dose-and time-dependent manner which was mediated by cell apoptosis.
Many drugs have been reported to sensitize tumor cells to TRAIL by DR4 and/or DR5 upregulation. Lee et al. demonstrated that the proteasome inhibitor ALLN significantly enhanced TRAIL-induced apoptosis by DR5 upregulation in LNCaP prostate cancer cells [12] . Vaculova et al. demonstrated that doxorubicin and etoposide markedly sensitized small cell lung cancer cells toward TRAIL-induced cell death. The drug-mediated sensitization of these cells was associated with DR5 upregulation and caspase-8 activation [13] . Ding et al. demonstrated that Glioblastoma-derived stem cells (GSC)-enriched neurospheres were resistant to TRAIL [14] . Cisplatin-mediated DR5 upregulation restores TRAIL apoptotic pathway in the neurospheres. Su et al. demonstrated that pemetrexed induced apoptosis through DR5 upregulation and discovered a synergistic effect of combination of pemetrexed and recombinant TRAIL [15] . DR5 knockdown abrogated the ability of pemetrexed to induce apoptosis. Mori et al. demonstrated that embelin could enhance the effect of TRAIL in the presence of FLIP antisense in pancreatic cancer cells [16] . Jiang et al. demonstrated that Embelin at about 3.759 μg/ml could enhance TRAIL-induced apoptosis in TRAIL-resistant A549 non-small cell lung cancer cells [17] . Our previous study showed that Embelin could induce leukemia cell apoptosis through XIAP downregulation and caspase-3 and 9 activation [11] . In this study, we also proved that Embelinenhanced TRAIL-induced apoptosis in HL-60 cells in a mechanism related to DR4 and DR5 upregulation. An interesting observation is the knockdown of only one death receptor, respectively, was sufficient to block TRAIL-induced cell death, which suggests a heterogenic TRAIL cell receptors trimerization upon binding of TRAIL.
Besides the abnormality of DR4 and DR5, TRAILinduced cell apoptosis can also be inhibited by a series of downstream mediators at the level of cFLIP or further downstream. The cFLIP can bind to capsase-8 and inhibit further caspase cascade which leads to apotosis inhibition [18] . Siegelin et al. found that the short isoform of cFLIP is a key regulator in TRAIL-Embelin-mediated apoptosis in malignant glioma [19] . The intrinsic apoptosis pathway is often required to efficiently trigger cell apoptosis after TRAIL stimulation. Insufficient amplification of the proteolysis cascade hinders activation of zymogens of executioner (or effector) caspase-3 and 7, which are responsible for the resistance of TRAIL. Overexpression of DcR2 confers resistance to TRAIL-mediated apoptosis [20] . Our present study showed that low-toxicity Embelin did not influence cFLIP, DcR1, and DcR2 expressions.
XIAP can also confer resistance to TRAIL-mediated apoptosis [7] . As an XIAP inhibitor, Embelin at low-toxicity concentration did not inhibit XIAP expression. This result demonstrated that the mechanism of low-toxicity Embelin sensitization of HL-60 cells to TRAIL-induced apoptosis is not closely related to XIAP inhibition.
A deficiency in caspase-8 expression can affect the function of TRAIL [21] . Our present study showed that caspase-8 could be activated by TRAIL combined with low-toxicity Embelin followed by the effector caspase-3 activation. And caspase-9 expression was also enhanced in the similar pattern of caspase-8 and caspase-3. These data demonstrated that lowtoxicity Embelin could enhance TRAIL-induced apoptosis through caspase activation.
At the level of effector caspases, XIAP has also been suggested to play a key role in preventing TRAIL-induced apoptosis [9, 22] . Our present study showed that low-toxicity Embelin alone or combined with TRAIL did not influence XIAP expression. This result indicated that low-toxicity Embelin-enhanced TRAIL-induced apoptosis was not mainly caused by XIAP expression changes.
In conclusion, the present study demonstrated that the XIAP inhibitor Embelin could enhance TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation and caspase activation. It provides a possibility for a novel chemotherapy strategy. Further investigations should be focused on the downstream signaling of DR4 and DR5.
Materials and methods

Reagents
Reagents used were 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Byotime, China), Annexin V-FITC/Propidium Iodide (PI), Z-VAD-FMK, Embelin, TRAIL and antibodies for Western blot (Sigma-aldrich, USA), PE-conjugated DR4 and DR5 antibodies (BioLegend, USA), and primers used for the quantitative real-time PCR and siRNA for transfection (BGI, China).
Cell culture HL-60 cells in logarithmic growth were grown in RPMI1640 supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin. The cells were cultured in suspension at 37°C and 5 % CO 2 in a humidified incubator and carried at 1×10 5 /ml, passaging two to three times weekly as needed.
Western blot
Cells were harvested at indicated times after indicated drug treatment. Cell debris were removed by centrifugation at 10,000 g for 10 min at 4°C. The resulting supernatants were resolved on a 10 % SDS-PAGE under denatured reducing conditions and transferred to nitrocellulose membranes. The membranes were blocked with 5 % non-fat dried milk at room temperature for 30 min and incubated with different primary antibodies. The membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies. The s i g n a l w a s v i s u a l i z e d u s i n g e n h a n c e d chemiluminescence. Fig. 3 Low-toxicity Embelin upregulated DR4 and DR5 expressions. a HL-60 cells were treated with Embelin of 10 μg/ml for 6, 12, 24, and 48 h, and mRNA was determined by quantitative real-time PCR. *P<0.05 indicates significant difference versus control group (Student's t test). b HL-60 cells were treated with Embelin of 10 μg/ml for 24 h, and DR4 and DR5 expressions were determined by Western blot. The equal loading of protein was confirmed by probing with ß-actin. c HL-60 cells were treated with Embelin of 10 μg/ml for 24 h, and surface expressions of DR4 and DR5 was determined by flow cytometry. *P<0.05 indicates significant difference versus control group (Student's t test). And representative results of surface expressions of d DR4 and e DR5. f HL-60 cells were pretreated with Embelin of 10 μg/ml for 24 h, and then TRAIL of 10 ng/ml was added for 24 h. Cell viability was determined by MTT assay Quantitative real-time PCR analysis Quantitative PCR was performed on a 7500 Applied Biosystems (Darmstadt, Germany) real-time PCR system as previously described [23] . Relative expression levels were calculated using the ΔΔCt-method. The sequences of the primers used for the quantitative real-time PCR were as follows: DR4:5′-ACCAGGAGGAGACAACCG-3′ and 5′-GGAGTCATTTCCAGCATCA-3′, DR5: 5′-TCTCCCATCC AACATCAC-3′ and 5′-GACATCCCAAACCAAATC-3′, and GAPDH :5′-AAGGCTGTGGGCAAGG-3′ and 5′-TGGAGGAGTGGGTGTCG-3′.
DR4 and DR5 transfection
The transfection procedures were carried out according to the instructions for Lipofectamine 2000 transfection reagent 24 h prior to the drug treatment. The 5×10 5 cells/well were incubated in 24-well plates and the final volume was 500 μl containing 20pmol RNA and 1.0 μl lipofectamine 2000. The sequences of siRNAs used were as follows (sense and antisense, respectively):siDR4 5′-r(CAAACUUCAUGAUCAA UCA)dTdT-3′ and 5′-r(UGAUUGAUCAUGAAGU UUG)dAdT-3′, siDR5 5′-r(GACCCUUGUGCUCGUU GUC)dTdT-3′ and 5′-r(GACAACGAGCACAAGGGUC)dT dT-3′ [24] , and control siRNA 5′-r(UUCUCCGAACGUGU CACGU)dTdT-3′ and 5′-r(ACGUGACACGUUCGGA GAA)dTdT-3′ [25] .
Measurement of cell viability and proliferation
Cell viability was evaluated by MTT assay. After washing the cells, culture medium containing 0.5 mg/ml of MTT was added to each well. The cells were incubated for 2 h at 37°C, the supernatant was removed and the formed formazan crystals in viable cells were solubilized with 0.11 ml of dimethyl sulfoxide. A 0.1-ml aliquot of each sample was then translated to 96-well plates, and the absorbance of each well was measured at 570 nm with ELISA reader. Data were expressed as a percentage of control measured in the absence of drugs.
Cell apoptosis measurement
For all assays, 5×10 5 /ml cells were seeded in six-well plates and cultured in a final volume of 200 μl. Cell viability was determined by staining with 10 μg/ml Annexin V-FITC conjugated with 5 μg/ml PI followed by flow cytometry (FACSCalibur, BD Biosciences). HL-60 cells were treated with TRAIL of 10 ng/ml alone or combined with Embelin of 10 μg/ml for 24 h then the cells were stained with Hoechst 33258 and observed by fluorescent microscopy (×40).
Measurement of cell surface DR4 and DR5 expressions
For all assays, 5×10 5 /ml cells were seeded in six-well plates and cultured in a final volume of 200 μl. Cell viability was determined by staining with 50 μg/ml PE-conjugated DR4 and DR5 antibodies followed by flow cytometry (FACSCalibur, BD Biosciences).
Statistical analysis
The data are expressed as means±SD, and the difference between two groups was evaluated using Student's t test. A probability level of 0.05 was used to establish significance.
Conclusions
Our present study suggested that Embelin-enhanced TRAILinduced cell apoptosis through DR4 and DR5 upregulation, indicating that combination of low-toxicity Embelin and TRAIL may become a novel antileukemia strategy.
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